← Back to Search

Intravenous Ketamine for Depression

Phase 3
Waitlist Available
Led By Pierre Blier, MD, PhD
Research Sponsored by University of Ottawa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3-4 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 5 Other Conditions
Pivotal Trial
No Placebo-Only Group

Summary

This trial compares intravenous ketamine to electroconvulsive therapy (ECT) for patients with depression who haven't responded to other treatments. Ketamine is given through an IV and works quickly to improve mood. The study aims to show that ketamine works faster, has fewer side effects, and is less costly than ECT. Ketamine has been found to elicit a rapid antidepressant response in repeated doses and may improve neurocognitive functioning.

Eligible Conditions
  • Depression
  • Major Depressive Disorder
  • Depression, Bipolar Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3-4 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3-4 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Montgomery-Asberg Depression Rating Scale

Side effects data

From 2023 Phase 1 & 2 trial • 15 Patients • NCT04916548
93%
dissociative symptoms
53%
dizziness
40%
dry mouth
27%
increased appetite
27%
sweating
27%
nausea
7%
decreased energy
7%
emotional indifference
7%
loss of sexual desire
7%
restlessness
7%
difficulty sleeping: too little
7%
headache
7%
tremors
7%
trouble achieving orgasm
100%
80%
60%
40%
20%
0%
Study treatment Arm
Intravenous Ketamine

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intravenous KetamineExperimental Treatment1 Intervention
Group II: Electroconvulsive TherapyActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

Ontario Shores Centre for Mental Health SciencesOTHER
13 Previous Clinical Trials
1,978 Total Patients Enrolled
5 Trials studying Depression
429 Patients Enrolled for Depression
Queen's UniversityOTHER
372 Previous Clinical Trials
123,767 Total Patients Enrolled
33 Trials studying Depression
6,963 Patients Enrolled for Depression
University Health Network, TorontoOTHER
1,520 Previous Clinical Trials
503,004 Total Patients Enrolled
55 Trials studying Depression
11,107 Patients Enrolled for Depression
~34 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top